Ep192: Kate Haviland on Following the Science to Precision Immunology

from The Long Run with Luke Timmerman · host Timmerman Report

Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.

Episode metadata supplied by the publisher feed · Published Jan 8, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Ep192: Kate Haviland on Following the Science to Precision Immunology

0:00 1:26:06

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Long Run with Luke Timmerman?

This episode is 1 hour and 26 minutes long.

When was this The Long Run with Luke Timmerman episode published?

This episode was published on January 8, 2026.

Can I download this The Long Run with Luke Timmerman episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!